Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCAP-AMP-VECP vs Biweekly CHOP in Aggressive ATLL
NCT00145002Phase 3Completed
- Sponsor
- Japan Clinical Oncology Group
- Start
- Aug 1998
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vincristine, cyclophosphamide, doxorubicin, prednisone, ranimustine in adult T-cell leukemia-lymphoma (ATLL), sponsored by Japan Clinical Oncology Group. Started Aug 1998; status: completed.
02
Drugs
vincristinecyclophosphamidedoxorubicinprednisoneranimustine
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00145002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145002.